Mariners face crucial offseason decisions on key players as they aim to build on ALCS run
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.
Mariners face crucial offseason decisions on key players as they aim to build on ALCS run
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.